XORTX Therapeutics Plans 1-for-5 Reverse Stock Split and Highlights Three Clinical Assets
XORTX Therapeutics will implement a 1-for-5 reverse stock split on April 6, 2026 to boost share price and satisfy TSX Venture and Nasdaq listing requirements. Its late-stage pipeline includes XRx-026 for gout, XRx-008 for ADPKD and XRx-101 targeting acute organ injuries from respiratory viruses.
1. Reverse Stock Split Scheduled
On April 6, 2026, XORTX Therapeutics will implement a 1-for-5 reverse stock split to raise its per-share trading price and maintain compliance with TSX Venture Exchange and Nasdaq listing standards. The initial consolidation date was delayed from March 27 to secure necessary shareholder and exchange approvals.
2. Clinical Pipeline Overview
XORTX’s pipeline comprises three late-stage assets: XRx-026 targeting gout, XRx-008 for Autosomal Dominant Polycystic Kidney Disease, and XRx-101 aimed at treating acute kidney and organ injuries from respiratory virus infections. All candidates have entered advanced clinical evaluations, reinforcing the company’s development focus.
3. Market Metrics and Capitalization
Shares of XORTX currently trade near $0.37, down 2.37% on March 30, with a 52-week range of $0.35 to $1.41. The company holds a market capitalization of roughly $515,342 and reported trading volume of 47,554 shares on the NASDAQ.